Tolvaptan in patients with autosomal dominant polycystic kidney disease

Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Jared J Grantham, Eiji Higashihara, Ronald D Perrone, Holly B Krasa, John Ouyang, Frank S Czerwiec, TEMPO 3:4 Trial Investigators, Alexander Maxwell

Research output: Contribution to journalArticlepeer-review

861 Citations (Scopus)


The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function.
Original languageEnglish
Pages (from-to)2407-18
Number of pages12
JournalNew England Journal of Medicine
Issue number25
Publication statusPublished - 20 Dec 2012


  • Adolescent
  • Adult
  • Benzazepines
  • Double-Blind Method
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Kidney
  • Male
  • Middle Aged
  • Organ Size
  • Polycystic Kidney, Autosomal Dominant
  • Receptors, Vasopressin
  • Sodium
  • Young Adult


Dive into the research topics of 'Tolvaptan in patients with autosomal dominant polycystic kidney disease'. Together they form a unique fingerprint.

Cite this